India Globalization Capital IGC Stock News

India Globalization Capital, Inc. (NYSEAMERICAN: IGC) is running for the top once again this morning, following up on the 300%+ gains the stock experienced yesterday. The gains come after the company received the green light from the FDA to move forward with a clinical trial centered around the idea that cannabis can be used as an option in the treatment of Alzheimer’s disease.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

IGC Wins Big On FDA Approval

Yesterday, India Globalization Capital told investors that the FDA has approved its request to move forward with a Phase 1 clinical trial. The trial will assess the company’s proprietary cannabinoid compound as a potential treatment option for dementia in patients with Alzheimer’s disease.

With the approval of the request, IGC will soon be the first comapny to assess cannabis as a treatment option for Alzheimer’s disease. Of course, if all goes well, that’s a huge win for the company and its investors.

Let’s not forget, Alzheimer’s is a massive market.

  • 5.5 million Americans currently suffer from Alzheimer’s disease.
  • 44 million consumers around the world suffer from Alzheimer’s disease.
  • By 2023, the Alzheimer’s disease market is expected to be worth $13.3 billion annually.

That’s a massive market. One that IGC would barely have to tap into in order to create substantial revenues for investors, considering that the entire company trades with a market cap of around $100 million, and that’s after yesterday’s tremendous gains.

Moreover, there’s not much competition in the Alzheimer’s space. While there are some drugs on the market, most of them are highly ineffective for the vast majority of patients. Also, there are no cures for the condition currently approved.

Should IGC develop a treatment that improves quality of life for these patients in a way that currently available treatments cannot, the company is sitting on the goose that lays the golden eggs.

The Bottom Line

The bottom line here is that there is good reason for the excitement surrounding India Globalization Capital. The company’s work may lead to an effective treatment to reduce dementia in Alzheimer’s patients, which would be overwhelmingly valuable.

Sure, there’s a long way to go, considering that the company is just moving into Phase 1 trials, but that’s where you get the discount. Having faith early. Should all go in the right direction, early faith here could lead to discount ownership of a blockbuster treatment option, making IGC stock one to watch closely.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Don’t Miss The Next Big Story

Join our free mailing list below to receive real-time news alerts!

Subscribe Today!

* indicates required


LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.